CA3216328A1 — Methods and compositions for treating mydriasis, glaucoma, and other ocular conditions
Assigned to Opus Genetics Inc · Expires 2022-10-27 · 4y expired
What this patent protects
The invention provides methods, compositions, and kits containing an alpha adrenergic antagonist such as phentolamine, either alone or in combination with a muscarinic acetylcholine receptor agonist such as pilocarpine, for treating conditions of the eye. Specifically, the invent…
USPTO Abstract
The invention provides methods, compositions, and kits containing an alpha adrenergic antagonist such as phentolamine, either alone or in combination with a muscarinic acetylcholine receptor agonist such as pilocarpine, for treating conditions of the eye. Specifically, the invention provides methods of treating patients suffering from mydriasis, glaucoma (such as angle-closure glaucomas or narrow angle attack), as well as improving aspects of vision in dim-light such as improved visual performance, reduced pupil diameter and reduced aberrant focus of scattered light.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.